Printer Friendly

Isis files patent infringement lawsuit against Santaris Pharma.

M2 EQUITYBITES-September 26, 2011-Isis files patent infringement lawsuit against Santaris Pharma(C)2011 M2 COMMUNICATIONS http://www.m2.com

Antisense technology company Isis Pharmaceuticals Inc (Nasdaq:ISIS) announced on Friday that it has filed a patent infringement lawsuit against Santaris Pharma A/S and Santaris Pharma A/S Corp in the US District Court of the Southern District of California.

Isis said that its infringement suit against Santaris is based upon Santaris' activities providing antisense drugs and antisense drug discovery services to several pharmaceutical companies. As alleged in the complaint, these activities are not protected under the exemption from patent infringement for drug development.

In the filed complaint, Isis alleges infringement of its US Patent No 6,326,199, entitled 'Gapped 2' Modified Oligonucleotides' and US Patent No. 6,066,500, entitled 'Antisense Modulation of Beta Catenin Expression' as the basis of its action.

Isis is reportedly the owner or exclusive licensee of approximately 1,550 issued patents worldwide that cover all facets of antisense drugs. One portion of Isis' patent estate includes patents covering basic oligonucleotide chemical modifications, drug designs that optimise therapeutic properties of antisense drugs and the use of antisense compounds in drug discovery.

((Comments on this story may be sent to info@m2.com)).END.PUB430>PDSeptember 26, 2011>JNM2 EQUITYBITES.PRICEDATENOT APPLICABLE.DAY

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Sep 26, 2011
Words:218
Previous Article:Precise Biometrics to provide Match-on-Card technology to Nigeria for national ID card.
Next Article:Kayne Anderson MLP Investment Company declares higher Q3 distribution of USD0.5025 per share.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters